ANDAINJECTIONINJECTABLE
Approved
Oct 2014
Lifecycle
Post-LOE
Competitive Pressure
60/100
Mechanism of Action
[ see Microbiology ()] .
Indications (15)
older) for the treatment of appendicitis (complicated by ruptureabscess)peritonitis caused by beta-lactamase producing isolates of Escherichia colithe following members of the Bacteroides fragilis group: Bolder) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureusby piperacillintazobactam-susceptible Acinetobacter baumanniiHaemophilus influenzaeKlebsiella pneumoniaePseudomonas aeruginosa (Nosocomial pneumonia caused by Pcomplicated skinskin structure infectionsincluding cellulitiscutaneous abscessespelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli